PAVmed, Inc.
(NASDAQ : PAVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
DXCMDexCom, Inc. 5.70%364.498.2%$1010.73m
ABTAbbott Laboratories 1.85%89.880.8%$687.47m
MDTMedtronic Plc 5.18%102.010.6%$656.19m
BDXBecton, Dickinson & Co. -0.68%241.891.0%$647.52m
DHRDanaher Corp. 2.61%173.190.7%$645.19m
TMOThermo Fisher Scientific, Inc. 1.72%354.131.0%$503.14m
BSXBoston Scientific Corp. 3.77%38.831.0%$437.50m
ISRGIntuitive Surgical, Inc. 5.05%592.762.4%$398.72m
SYKStryker Corp. 4.48%206.951.3%$354.31m
INOInovio Pharmaceuticals, Inc. 0.42%11.936.3%$337.96m
ALGNAlign Technology, Inc. 10.82%288.216.4%$324.61m
WSTWest Pharmaceutical Services, Inc. 0.16%205.721.6%$293.42m
BAXBaxter International, Inc. 0.60%89.161.8%$247.08m
ZBHZimmer Biomet Holdings, Inc. 6.12%137.441.7%$203.62m
QDELQuidel Corp. -2.07%153.647.7%$202.30m

Company Profile

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.